Sign in to continue:

Tuesday, March 10th, 2026

Cohen & Company Inc. 2025 Annual Report: Financials, Investments, and Segment Disclosures (10-K Filing)

Cohen & Co Inc. 2025 Annual Report: Key Details for Investors

Cohen & Co Inc. 2025 Annual Report: Key Insights for Investors

Summary of Key Points

  • Business Overview: Cohen & Co Inc., headquartered in Philadelphia, operates as a security broker, dealer, and flotation company, with a diversified financial services portfolio.
  • Share Structure:
    • Preferred Stock: 50,000,000 shares authorized, 27,413,098 issued and outstanding as of December 31, 2025.
    • Common Stock: 100,000,000 shares authorized, 2,130,063 issued and outstanding as of December 31, 2025 (up from 2,040,052 in 2024).
    • Restricted/Common Stock Awards: 380,008 shares in 2025 (down from 404,791 in 2024), potentially dilutive to shareholders.
  • Operating Segments: The company operates three segments: Capital Markets, Asset Management, and Principal Investing.
  • Cybersecurity: The company has confirmed robust cybersecurity oversight, including third-party risk management. No material adverse cybersecurity events reported.
  • Insider Trading & Governance: Insider trading policies and award timing procedures are in place and up-to-date.
  • Dividend: \$1.00 per share common stock dividend declared in 2023; no explicit dividend data provided for 2025.
  • Junior Subordinated Notes:
    • Total par amount owed: \$49.6 million.
    • Notes recorded at a discount; effective yield to maturity as of December 31, 2025, is a striking 19.07% (assuming the current variable rate holds).
    • This high yield may reflect market risk perceptions or unique capital structure dynamics.
  • Goodwill & Intangibles: No goodwill impairment losses reported for several consolidated entities in 2023-2025.
  • Noncontrolling Interest: Company maintains a 51% voting interest in a key LLC subsidiary.
  • Commitment & Contingencies: No outstanding lines of credit as of December 31, 2024.
  • Segment Disclosures: Advisory and management fees received in 2024: \$24.3 million.
  • Antidilutive Securities: Several classes of restricted stock and LLC units could become dilutive if company performance improves.

Potentially Price-Sensitive Highlights

  • High Yield on Debt: The 19.07% yield on junior subordinated notes is exceptionally high for a regulated financial firm. This could indicate either high risk (potential solvency concerns or market distrust) or aggressive capital management. Investors should monitor this closely for impact on future refinancing, interest expense, and overall risk profile.
  • Equity Structure Changes: Issued and outstanding common shares increased by approximately 90,000 year-over-year, and restricted shares remain significant. This may cause dilution, affecting per-share metrics and possibly share value, especially if further awards are made or shares released from restriction.
  • Cybersecurity Status: A positive note for shareholders—robust controls and board oversight, with no material cybersecurity incidents. This reduces the near-term risk of negative price impact from cyber events.
  • Stable Goodwill & Intangibles: No impairment losses provide some reassurance regarding asset quality and balance sheet stability.
  • No New Dividends Disclosed for 2025: Lack of explicit dividend declaration for 2025 could be notable for income-focused investors, especially following a \$1.00 per share dividend in 2023.
  • Segment Growth & Fee Revenue: Advisory and management fee income remains robust; any acceleration or decline here could materially impact future earnings and, therefore, share price.
  • Noncontrolling Interest: The 51% voting interest in a major LLC subsidiary may give Cohen & Co. effective control but also exposes it to both upside and downside risk from this entity’s performance.

Additional Detailed Observations

  • Preferred Stock Structure: The company has multiple preferred stock series (Series C, E, F, and others), with unique voting and conversion features (e.g., 10:1 vote ratio in some series). Changes in these features or new issuances could affect common shareholder rights and value.
  • Warrants: There are outstanding warrants, including rights agreements calling for conversion ratios (e.g., 10 securities per warrant in some cases), which could add to dilution risk if exercised.
  • No Goodwill Impairment: For key consolidated entities such as Alesco Financial Inc, no impairment losses were recorded from 2023-2025, supporting the carrying value of acquired intangible assets.
  • Segment Reporting: The company continues to report three operating and reportable segments, which may reflect a diversified but potentially complex business model.
  • No Outstanding Lines of Credit: As of December 31, 2024, there were no outstanding amounts under certain credit facilities, suggesting limited short-term liquidity risk at that time.
  • Potential Dilution from Awards: The presence of a large pool of restricted or unvested awards (over 380,000 shares in 2025) could dilute existing shareholders if vesting accelerates or performance conditions are met.
  • Complex Capital Structure: The company’s equity and debt structure, including various classes of preferred stock, restricted units, and high-yield debt, increases both opportunity and risk for investors.

Investor Takeaways

Cohen & Co Inc. presents a mixed picture for investors. The company’s robust fee income, stable goodwill values, and strong cybersecurity oversight are positives. However, the high yield on junior subordinated notes signals elevated risk or potential distress. The ongoing issuance of new common shares and the existence of a large pool of restricted shares also raise dilution concerns.

Investors should carefully monitor any changes to the company’s capital structure, dividend policy, and fee income trends, as these could quickly become price-moving events. The complexity of the company’s financial instruments and equity structure, as well as the high cost of debt, suggest that Cohen & Co Inc. may face both opportunities and challenges in the years ahead.


Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult their financial advisors before making any investment decisions regarding Cohen & Co Inc. The author is not responsible for any actions taken based on the information provided herein.


View Cohen & Co Inc. Historical chart here



Cartesian Therapeutics Reports 2025 Financial Results, Advances Descartes-08 Cell Therapy in Autoimmune Diseases and Myasthenia Gravis Phase 3 Trial

Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update Cartesian Therapeutics (NASDAQ: RNAC) Reports Full Year 2025 Financial Results and Strategic Pipeline Advancements Key Highlights for Investors Enrollment Progresses in Phase...

Enhabit, Inc. Credit Agreement 2026: Key Terms, Definitions, and Loan Structure Summary

Enhabit, Inc. Announces Amended and Restated Credit Agreement Enhabit, Inc. Announces Amended and Restated Credit Agreement with Major Financial Institutions Key Developments Shareholders Must Know Enhabit, Inc. (NYSE: ), a publicly-traded provider of home...

Darling Ingredients Inc. 8-K Filing February 25, 2026 – Company Details, SEC Data, and Press Release

Darling Ingredients Inc. Board Changes: Retirement and New Appointment Darling Ingredients Inc. Announces Board Changes: Director Retirement and New Appointment Key Highlights Director Retirement Announced: Gary W. Mize, a member of the Board of...

   Ad